Literature DB >> 2466854

Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy.

Y Tomino1, W Inoue, M Yagame, Y Nomoto, H Sakai, K Ito, K Nagaoka, N Ikeda.   

Abstract

Measurement of sialic acid and acute phase reactant (APR) proteins in sera of patients with diabetic nephropathy was performed. Twenty-six patients with non-insulin-dependent diabetes mellitus (NIDDM) were examined. The levels of sialic acid in sera, with or without treatment of neuraminidase, were measured by the thiobarbiturate method. The levels of alpha 1-antitrypsin (alpha 1-AT), alpha 1-acid glycoprotein (alpha 1-AG) or alpha 2-macroglobulin (alpha 2-MG) were measured by laser nephelometry. The levels of sialic acid or APR proteins in sera of patients with diabetic nephropathy were increased markedly. There was a significant correlation between the levels of sialic acid and those of alpha 1-AT in sera of patients with NIDDM. The mobility of alpha 1-AT in sera of patients with NIDDM treated with neuraminidase was decreased markedly in the immunofixation test. It is suggested that the increase of APR proteins in diabetic sera is mainly composed of sialic acid in patients with NIDDM with or without nephropathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2466854     DOI: 10.1016/s0891-6632(88)80004-7

Source DB:  PubMed          Journal:  J Diabet Complications        ISSN: 0891-6632


  3 in total

1.  Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy.

Authors:  Jamshid Roozbeh; Ahmad Merat; Farahnaz Bodagkhan; Raha Afshariani; Hooman Yarmohammadi
Journal:  Int Urol Nephrol       Date:  2011-01-05       Impact factor: 2.370

2.  Total and lipid bound sialic acid levels in patients with polycystic ovary syndrome.

Authors:  Ali Ozcan; Aykan Yücel; Volkan Noyan; Nevin Sağsöz; Osman Cağlayan
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-06-01

3.  Levels of serum sialic acid and thiobarbituric acid reactive substances in subjects with impaired glucose tolerance and type 2 diabetes mellitus.

Authors:  Gulsen Yilmaz; Fatma Meric Yilmaz; Yalcin Aral; Dogan Yucel
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.